NCT05709106View on ClinicalTrials.gov

A Prospective Real World Study of Rimegepant in the Treatment of Migraine

RecruitingOBSERVATIONAL
Enrollment

100

Participants

Timeline

Start Date

January 11, 2023

Primary Completion Date

January 31, 2025

Study Completion Date

December 30, 2025

Conditions
Migraine
Interventions
DRUG

Rimegepant 75 MG

Migraine patients would take Rimegepant 75 MG to treat or prevent a migraine attack and patients would be followed up for 1 year

Trial Locations (1)

571434

RECRUITING

Ruijin-Hainan Hospital Shanghai Jiao Tong University School of Medicine, Boao

All Listed Sponsors
lead

Ruijin-Hainan Hospital Shanghai Jiao Tong University School Of Medicine

OTHER